Raxibacumab, clinically designated as PAmAb ABthrax, is a novel treatment approach to the disease . This single protein, designed by the company , uniquely interacts with the protective factor of Bacillus anthracis, significantly preventing its function to induce infection . The process of Raxibacumab requires disrupting toxin attachment to patient